Management of vaccinations in patients with non-Hodgkin lymphoma.
Michele MerliAndrea CostantiniStefano TermiteDavide Fiore BavaroCarla MinoiaErika MeliStefano LuminariGuido GiniPublished in: British journal of haematology (2024)
Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS-CoV-2-related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine-induced immune responses after anti-CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients. In this review, we summarize the existing data about COVID-19 and other vaccine's efficacy in patients with NHL and propose multidisciplinary team-based recommendations for the management of vaccines in this specific group of patients.
Keyphrases
- end stage renal disease
- sars cov
- ejection fraction
- newly diagnosed
- immune response
- peritoneal dialysis
- prognostic factors
- palliative care
- coronavirus disease
- infectious diseases
- patient reported outcomes
- monoclonal antibody
- risk factors
- intensive care unit
- inflammatory response
- toll like receptor
- oxidative stress
- high glucose
- patient reported
- stress induced
- quality improvement
- climate change
- diabetic rats